Investing8 天
Bicycle Therapeutics stock target cut, buy rating held on drug development
On Monday, H.C. Wainwright adjusted its price target for shares of Bicycle Therapeutics (NASDAQ:BCYC), a biopharmaceutical company, reducing it to $33.00 from the previous $55.00. The stock ...
Business Insider6 天
Bicycle Therapeutics price target lowered to $26 from $32 at JMP Securities
JMP Securities analyst Reni Benjamin lowered the firm’s price target on Bicycle Therapeutics (BCYC) to $26 from $32 and keeps an Outperform rating on the shares. The firm is pushing back its ...
Business Insider11 天
Bicycle Therapeutics price target lowered to $17 from $28 at B. Riley
B. Riley lowered the firm’s price target on Bicycle Therapeutics (BCYC) to $17 from $28 and keeps a Neutral rating on the shares. The stock dropped 35% intraday and now trading near cash after ...
techtimes12 天
New York's Proposed E-Bike Law Sparks Debate: Safety Measure or Target on Marginalized ...
New York's proposed e-bike law sparks outrage as critics argue it unfairly targets marginalized communities while ignoring ...
pharmaphorum3 天
Roche rings Bicycle bell again, grabbing another cancer target
Bicycle's immuno-oncology pipeline is headed by BT7480, a tumour-targeted immune cell agonist (TICA) that binds to Nectin-4 on cancer cells and stimulates CD137 on immune cells, driving an immune ...
Investing8 天
Bicycle Therapeutics stock target cut, rating held on clinical data
On Monday, B.Riley updated its assessment of Bicycle Therapeutics (NASDAQ:BCYC) shares, significantly reducing the biopharmaceutical company's price target from $28.00 to $17.00 while maintaining ...
kalkinemedia4 天
Why Did Bicycle Therapeutics Shares Drop After Recent Price Target Revision?
Highlights,Bicycle Therapeutics plc focuses on developing targeted therapies for diseases.,JMP Securities adjusted its price target while maintaining its market outperform rating.,Trading volume ...